Refined high-content imaging-based phenotypic drug screening in zebrafish xenografts
Year: 2023
Type: article
Abstract: Zebrafish xenotransplantation models are increasingly applied for phenotypic drug screening to identify small compounds for precision oncology. Larval zebrafish xenografts offer the opportunity to perform drug screens at high-throughput in a complex in vivo environment. However, the full potential of the larval zebrafish xenograft model has not yet been realized and several steps of the drug screening workflow still await automation to increase throughput. Here, we present a robust workflow for drug screening in zebrafish xenografts using high-content imaging. We established embedding methods for high-content imaging of xenografts in 96-well format over consecutive days. In addition, we provide strategies for automated imaging and analysis of zebrafish xenografts including automated tumor cell detection and tumor size analysis over time. We also compared commonly used injection sites and cell labeling dyes and show specific site requirements for tumor cells from different entities. We demonstrate that our setup allows us to investigate proliferation and response to small compounds in several zebrafish xenografts ranging from pediatric sarcomas and neuroblastoma to glioblastoma and leukemia. This fast and cost-efficient assay enables the quantification of anti-tumor efficacy of small compounds in large cohorts of a vertebrate model system in vivo. Our assay may aid in prioritizing compounds or compound combinations for further preclinical and clinical investigations.
Source: npj Precision Oncology
Authors: C. Sturtzel, S. Grissenberger, P. Bozatzi, E. Scheuringer, A. Wenninger-Weinzierl, Z. Zajec, J. Dernovšek, S. Pascoal, V. Gehl, A. Kutsch, A. Granig, F. Rifatbegovic, M. Carre, A. Lang, I. Valtingojer, J. Moll, D. Lötsch, F. Erhart, G. Widhalm, D. Surdez, O. Delattre, N. André, J. Stampfl, T. Tomašič, S. Taschner-Mandl, M. Distel
Institutions: St. Anna Children's Cancer Research Institute, University of Ljubljana, TU Wien, Centre National de la Recherche Scientifique, Inserm, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Centre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, Hôpital de la Timone, Comprehensive Cancer Center Vienna, Medical University of Vienna, Sanofi (France), University of Zurich, Université Paris Sciences et Lettres, Institut Curie
Language: English
Subfield: Cell Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,490
Funders: Alex's Lemonade Stand Foundation for Childhood Cancer, Sanofi, European Commission, Vienna Science and Technology Fund, Österreichischen Akademie der Wissenschaften, Javna Agencija za Raziskovalno Dejavnost RS, Österreichische Forschungsförderungsgesellschaft, OeAD-GmbH, Horizon 2020 Framework Programme
Awards: G1408658188, Medicinal chemistry - drug design, synthesis and evaluation, G2703145218, G281475060, Development of novel Hsp90 inhibitors with anticancer activity, ITCC Pediatric Preclinical POC Platform – Sofia ref.: 116064, G6228105631, G6475742650, Ultra-high-risk pediatric cancer - combinatorial drivers and therapeutic targets for precision medicine
OpenAlex ID: W4377023484
